Your Evidence-Based Guide to Weight Loss Peptides

“Tirzepatide demonstrates greater weight loss and glycemic control than semaglutide in clinical trials, achieving up to 20.9% body weight reduction versus 14.9-16.0% with semaglutide. However, semaglutide has proven cardiovascular benefit (SELECT trial), longer post-marketing safety data, and an oral formulation option. Both are FDA-approved, well-tolerated, and represent major advances in metabolic medicine. The choice between them depends on clinical priorities: maximum weight loss favors tirzepatide, while cardiovascular risk reduction and formulation flexibility favor semaglutide.”

“Semaglutide is the established gold standard with FDA approval, proven cardiovascular benefit, extensive clinical data, and multiple formulation options. Retatrutide's triple agonism shows promise for greater weight loss and liver fat reduction, but remains investigational with Phase 2 data only. Phase 3 results will determine whether retatrutide's early advantages translate into meaningful clinical superiority.”

“Tirzepatide is the proven choice with FDA approval and extensive clinical data; Retatrutide shows potential for greater efficacy through triple-agonism but awaits Phase 3 results”

“Tirzepatide is substantially superior to liraglutide in weight loss efficacy (20.9% vs 8.0%), glycemic control (HbA1c -2.58% vs -1.5%), and dosing convenience (weekly vs daily injection). The dual GIP/GLP-1 mechanism provides complementary metabolic benefits that a single GLP-1 agonist cannot match. Liraglutide's main advantage is its completed cardiovascular outcomes trial (LEADER) demonstrating 13% MACE reduction, while tirzepatide's CVOT is still pending. For patients where cardiovascular risk reduction is the primary goal and a proven CVOT is required, liraglutide (or semaglutide) may be preferred. For maximum weight loss or glycemic control, tirzepatide is the clear choice.”